ProfileGDS5678 / 1436394_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 86% 86% 85% 86% 90% 87% 85% 83% 89% 91% 88% 89% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.75388
GSM967853U87-EV human glioblastoma xenograft - Control 26.6493586
GSM967854U87-EV human glioblastoma xenograft - Control 36.5840986
GSM967855U87-EV human glioblastoma xenograft - Control 46.5089285
GSM967856U87-EV human glioblastoma xenograft - Control 56.587486
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.9067890
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.5163287
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3462285
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0122183
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.0445589
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.3312891
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.9627688
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.0900789
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.0584789